Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 4, 2025Idorsia Ltd (SIX: IDIA) today announced its ...

Nxera Pharma inks agreement with Holling Bio-Pharma to commercialize daridorexant in Taiwan: Tokyo, Japan Monday, March 3, 2025, 16:00 Hrs [IST] Nxera Pharma Co., Ltd. announces t ...

Daridorexant is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating ...

NLS Pharmaceutics Ltd., in collaboration with Aexon Labs Inc., has announced new preclinical findings on AEX-2, a non-sulfonamide dual orexin receptor agonist (DOXA) with potential for narcolepsy and ...

NLS Pharmaceutics (NLSP) announces new preclinical findings on AEX-2, reinforcing its potential as a first-in-class non-sulfonamide dual orexin ...

Problems with sleep likely develop before motor symptoms in people with amyotrophic lateral sclerosis, a new study shows.

Amyotrophic lateral sclerosis (ALS), also known as Charcot’s disease, or Lou Gehrig’s disease, is a severe neurodegenerative ...

For most of us, getting less than seven hours of sleep translates into grogginess, sluggish thinking, and an overwhelming ...

Bial-Portela & Ca SA has identified orexin OX1 receptor antagonists reported to be useful for the treatment of cognitive, sleep, anxiety and eating disorders, depression, obesity, schizophrenia, ...

QUVIVIQ™ is a novel dual orexin receptor agonist that was successfully developed through a Phase 3 trial by Nxera Pharma Japan (“NPJ,” a wholly owned subsidiary of Nxera Pharma). QUVIVIQ™ was launched ...

Q4 2024 Management View CEO Richard Pops highlighted 2024 as a transformative year focused on profitability and pipeline development, achieving over $1.5 billion in revenue and $450 million in EBITDA ...

Nevertheless, observing the symptoms of COVID-19 might lead to new perspectives in understanding TTS pathophysiology, as some of the symptoms of the COVID-19 infection could be assessed in the context ...